Generation Bio Past Earnings Performance

Past criteria checks 0/6

Generation Bio's earnings have been declining at an average annual rate of -17.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 98.6% per year.

Key information

-17.5%

Earnings growth rate

41.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate98.6%
Return on equity-139.3%
Net Margin-782.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11
Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14
Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Generation Bio EPS misses by $0.01

Nov 10

Revenue & Expenses Breakdown

How Generation Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:GBIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2419-145560
30 Jun 2413-158580
31 Mar 2410-169620
31 Dec 236-127650
30 Sep 233-124650
30 Jun 231-127650
31 Mar 230-134680
31 Dec 220-137670
30 Sep 220-13562-56
30 Jun 220-13659-37
31 Mar 220-12950-17
31 Dec 210-119440
30 Sep 210-1124963
30 Jun 210-1014359
31 Mar 210-883455
31 Dec 200-81320
30 Sep 200-722152
30 Jun 200-682147
31 Mar 200-652442
31 Dec 190-612241
31 Dec 180-361225

Quality Earnings: GBIO is currently unprofitable.

Growing Profit Margin: GBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GBIO is unprofitable, and losses have increased over the past 5 years at a rate of 17.5% per year.

Accelerating Growth: Unable to compare GBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: GBIO has a negative Return on Equity (-139.29%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies